BETA
Your AI-Trained Oncology Knowledge Connection!
Savolitinib Plus Osimertinib Elicits Durable Responses in MET+ Advanced NSCLC
Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations and MET overexpression.
Dato-DXd Combination Is Effective in Post-TKI NSCLC
Combination therapy of osimertinib and datopotamab deruxtecan shows promising efficacy in advanced NSCLC, warranting further phase 3 studies.
Cilta-Cel Bests SOC in Refractory Multiple Myeloma
Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.
Nine Staff Management Essentials for Physicians
Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.
ALLELE Trial Confirms Clinical Activity of Tabelecleucel in Lymphoproliferative Disease
Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.
Cellular Therapies Show Safety in B-Cell Malignancies
The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.
Expanded Approaches Focus on Balancing Efficacy and Toxicity in NSCLC
President Trump Issues Executive Orders Signaling Goals for Health Care
President Donald J. Trump has signaled that lowering the costs of prescription drugs will be a priority for his second term.
